PBM Key Statistics, Chart & Performance
The current stock price of PBM is 1.76 USD. In the past month the price decreased by -29.96%. In the past year, price decreased by -90.68%.
PBM Latest News, Press Relases and Analysis
PBM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About PBM
Company Profile
Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Company Info
PSYENCE BIOMEDICAL LTD
121 Richmond Street West Penthouse, Suite 1300
TORONTO ONTARIO V6E 3Z3 CA
CEO: John Plourde
Employees: 12
Phone: 17744604171
PSYENCE BIOMEDICAL LTD / PBM FAQ
Can you describe the business of PSYENCE BIOMEDICAL LTD?
Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Can you provide the latest stock price for PSYENCE BIOMEDICAL LTD?
The current stock price of PBM is 1.76 USD. The price decreased by -2.76% in the last trading session.
Does PBM stock pay dividends?
PBM does not pay a dividend.
How is the ChartMill rating for PSYENCE BIOMEDICAL LTD?
PBM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists PBM stock?
PBM stock is listed on the Nasdaq exchange.
Should I buy PBM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PBM.
PBM Technical Analysis
PBM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |